SHOT: Trump Unveils Another Backdoor Deal with Big Pharma. Yesterday, Trump unveiled his deal with Regeneron that he promises will lower costs, but as with his other deals with big drug companies, “the details of the agreements remain private.” [The Hill, 2/24/26]
CHASER: “Regeneron Shares Up on Trump Drug Pricing Deal.” After the deal went live, Regeneron’s shares rose 2.6%. Similar to Trump’s previous deals with big drug companies, Regeneron was promised 3 years of tariff relief in exchange for lowering drug prices on TrumpRx. [Barron’s, 2/23/26]
LIME: These Backroom Deals Benefit Big Pharma Far More Than Americans. Trump’s deals cost the big drug companies virtually nothing and line their profits with savings on tariffs and future drug pricing efforts, while failing to deliver on lower drug prices for working Americans. Half of the drugs on the website have cheaper generics widely available, many would be cheaper through insurance, and less than half the drugs are among the 300 most commonly prescribed. [Protect Our Care, 2/9/26]